Saama commissioned BioPharma Dive to survey pharma executives on the clinical research impact of COVID-19. More than a third of the companies represented in the survey were conducting clinical studies related to COVID-19, but the pandemic also had an impact on the nearly two thirds of companies that were studying other conditions.
Nearly two-thirds of respondents were likely to adopt an integrated data solution to improve clinical trial performance.
More than a quarter of respondents were eager to implement a remote monitoring solution.
Respondents who experienced clinical study delays related to COVID-19 have different opinions on when research will resume:
Not sure / Trials on hold
Sometime in 2021
2022 or later
Never, they have been canceled
Difficult / Time-
Nearly three-quarters of respondents were likely to adopt an integrated data solution to improve clinical trial performance.
More than half of respondents were likely to implement a technology platform to speed scientific data analysis.
More than a quarter of respondents expressed the need for an analytics solution that integrates clinical and biomarker data to enhance translational research.
While the pandemic has caused many problems for pharma, it has created opportunities for new treatments and vaccines and accelerated the much-needed digital transformation of the industry. Let Saama modernize your data collection and analytics efforts.Download Report